Aquestive Therapeutics, Inc. (AQST) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. Aquestive Therapeutics, Inc. is a pharmaceutical company developing medicines using innovative delivery technologies, primarily focusing on the Anaphylm (epinephrine) platform for anaphylaxis and the Libervant (diazepam) buccal film for seizure clusters. The company operates as a single segment, serving as the exclusive manufacturer for its licensed products (e.g., Suboxone, Ondif) and advancing its proprietary pipeline.
Key Financial Metrics
| Metric (in thousands) | Q2 2025 | Q2 2024 | 6M 2025 | 6M 2024 |
|---|---|---|---|---|
| Total Revenues | $10,003 | $20,099 | $18,723 | $32,152 |
| Net Loss | $(13,548) | $(2,745) | $(36,478) | $(15,573) |
| Loss Per Share (Basic/Diluted) | $(0.14) | $(0.03) | $(0.37) | $(0.19) |
| Cash and Cash Equivalents | $60,536 | $89,870 | $60,536 | $89,870 |
| Net Cash Used in Operating Activities | N/A | N/A | $(31,314) | $(17,390) |
| Total Debt (Notes Payable, net) | $31,843 | $32,500 | $31,843 | $32,500 |
| Stockholders' Deficit | $(72,590) | $(35,479) | $(72,590) | $(35,479) |
Note: The company reported a negative gross margin for Q2 2025 due to negative proprietary product revenue (returns allowance adjustments) offsetting manufacturing revenue.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 50% in Q2 2025 and 42% for the six months ended June 30, 2025, compared to the prior year. This was primarily driven by a 93% drop in license and royalty revenue, attributed to the absence of one-time deferred revenue recognitions from terminated agreements with Haisco and MTPA in the prior year.
- Expense Increases: Selling, General, and Administrative (SG&A) expenses increased 12% in Q2 and 44% for the six months, driven by higher commercial spending, regulatory fees (including the Anaphylm PDUFA fee), and accelerated recognition of regulatory fees for Libervant.
- Net Loss Expansion: Net loss widened significantly due to the revenue decline and increased SG&A, despite relatively stable R&D and manufacturing costs.
- Equity Dilution: The company issued approximately 7.46 million shares under its At-The-Market (ATM) facility during the first six months of 2025, raising net proceeds of approximately $21.3 million.
Guidance, Outlook, and Risks
- Anaphylm Progress: The FDA accepted the New Drug Application (NDA) for Anaphylm on June 16, 2025, with a PDUFA target action date of January 31, 2026. The company plans a product launch in Q1 2026 if approved.
- Libervant Regulatory Status: Following a District Court ruling in February 2025 vacating the FDA's approval of Libervant for pediatric patients (ages 2-5) due to Orphan Drug Exclusivity (ODE) disputes with Neurelis, the FDA converted the approval to "tentative." Aquestive has ceased marketing activities in the U.S. while pursuing an appeal and a request for clinical superiority determination.
- Liquidity: Management states that existing cash ($60.5 million), expense management, and access to the ATM facility provide liquidity for at least the next 12 months. However, the company expects to incur significant operating losses and negative cash flows for the foreseeable future.
- Debt Obligations: The company holds $45 million in 13.5% Senior Secured Notes due 2028. Principal amortization payments are scheduled to begin in June 2026.
- Legal Risks: Significant contingencies include the Neurelis litigation regarding Libervant, ongoing Suboxone product liability litigation (MDL), and potential impacts from new U.S. tariff policies on pharmaceutical raw materials.
Investor Verification Checklist
- Libervant Market Access: Verify the status of the appeal regarding the District Court's vacatur of Libervant's pediatric approval and the FDA's response to the clinical superiority request.
- Anaphylm Approval Timeline: Monitor the FDA's review progress toward the January 31, 2026, PDUFA date and the potential requirement for an advisory committee meeting.
- Cash Burn Rate: Assess the sustainability of the $60.5 million cash balance given the $31.3 million operating cash burn in the first half of 2025 and upcoming debt principal payments in 2026.
- Revenue Concentration: Review the dependency on Indivior (Suboxone) and Hypera (Ondif), which represented approximately 90% of total revenue in the first half of 2025.
- Debt Covenants: Confirm compliance with the 13.5% Notes covenants, specifically the requirement for $100 million in net revenues to access the optional Asset-Based Lending (ABL) facility.